Xymedon

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341434

CAS#: 14716-32-6

Description: Xymedon is a biochemical.

Chemical Structure

img
Xymedon
CAS# 14716-32-6
Instruction

Theoretical Analysis

MedKoo Cat#: 341434
Name: Xymedon
CAS#: 14716-32-6
Chemical Formula: C8H12N2O2
Exact Mass: 168.09
Molecular Weight: 168.196
Elemental Analysis: C, 57.13; H, 7.19; N, 16.66; O, 19.02

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Xymedon; Ximedone; Ximedon.

IUPAC/Chemical Name: 2(1H)-Pyrimidinone, 1-(2-hydroxyethyl)-4,6-dimethyl-

InChi Key: JLKVZOMORMUTDG-UHFFFAOYSA-N

InChi Code: InChI=1S/C8H12N2O2/c1-6-5-7(2)10(3-4-11)8(12)9-6/h5,11H,3-4H2,1-2H3

SMILES Code: O=C1N=C(C)C=C(C)N1CCO

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 168.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Siprov AV, Solovyova MA. Morphofunctional State of Erythrocytes in Rats with Walker-256 Carcinoma Treated with Docetaxel and Xymedon. Bull Exp Biol Med. 2017 Nov;164(1):44-48. doi: 10.1007/s10517-017-3923-7. Epub 2017 Nov 9. PubMed PMID: 29119390.

2: Vyshtakalyuk AB, Nazarov NG, Zobov VV, Abdulkhakov SR, Minnekhanova OA, Semenov VE, Galyametdinova IV, Cherepnev GV, Reznik VS. Evaluation of the Hepatoprotective Effect of L-Ascorbate 1-(2-Hydroxyethyl)-4,6-Dimethyl-1,2-Dihydropyrimidine-2-One Upon Exposure to Carbon Tetrachloride. Bull Exp Biol Med. 2017 Jan;162(3):340-342. doi: 10.1007/s10517-017-3610-8. Epub 2017 Jan 14. PubMed PMID: 28091907.

3: Povysheva TV, Semenov VE, Galyametdinova IV, Reznik VS, Knni KS, Kolesnikov PE, Chelyshev YA. New Xymedon Analogues for Stimulation of Posttraumatic Regeneration of the Spinal Cord in Rats. Bull Exp Biol Med. 2016 Dec;162(2):220-224. Epub 2016 Dec 1. PubMed PMID: 27905041.

4: Valeeva IKh, Titarenko AF, Khaziakhmetova VN, Ziganshina LE. [ANTIOXIDANT ACTIVITY OF XYMEDONE IN RATS WITH CHRONIC AUTOIMMUNE INFLAMMATION]. Eksp Klin Farmakol. 2016;79(1):33-7. Russian. PubMed PMID: 27159956.

5: Vyshtakalyuk AB, Nazarov NG, Zobov VV, Semenov VE, Galyametdinova IV, Tcherepnev GV, Reznic VS. Pirimidine derivatives as hepatoprotective agents. Int J Risk Saf Med. 2015;27 Suppl 1:S78-9. doi: 10.3233/JRS-150698. PubMed PMID: 26639723.

6: Valeeva IKh, Titarenko AF, Khaziakhmetova VN, Ziganshina LE. Anti-inflammatory and anti-oxidant properties: Is there a link? Int J Risk Saf Med. 2015;27 Suppl 1:S67-8. doi: 10.3233/JRS-150693. PubMed PMID: 26639717.

7: Melnikova NB, Korobko VM, Gulenova MV, Gubskaya VP, Fazlleeva GM, Zhiltsova OE, Kochetkov EN, Poddel'sky AI, Nuretdinov IA. Nitroxide malonate methanofullerene as biomimetic model of interaction of nitroxide species with antioxidants. Colloids Surf B Biointerfaces. 2015 Dec 1;136:314-22. doi: 10.1016/j.colsurfb.2015.09.026. Epub 2015 Sep 18. PubMed PMID: 26422596.

8: Vyshtakaliuk AB, Nazarov NG, Porfiriev AG, Zueva IV, Minnechanova OA, Mayatina OV, Reznik VS, Zobov VV, Nicolskyi EE. The influence of the Xymedon preparation (Hydroxyethyldimethyldihydropyrimidine) on the rat liver recovery under toxic damage induced by carbon tetrachloride. Dokl Biochem Biophys. 2015;462:143-6. doi: 10.1134/S1607672915030011. Epub 2015 Jul 12. PubMed PMID: 26163205.

9: Revin VV, Filatova SM, Syusin IV, Yazykova MY, Revina ES, Gromova NV, Devyatkin AA. Study of correlation between state and composition of lipid phase and change in erythrocytes structure under induction of oxidative processes. Int J Hematol. 2015 May;101(5):487-96. doi: 10.1007/s12185-015-1758-4. Epub 2015 Feb 24. PubMed PMID: 25708315.

10: Martusevich AK, Sidorova MV, Mel'nikova NB, Solov'eva AG, Peretiagin SP. [Effect of phytic acid and its derivatives on blood lipid peroxidation state in vitro]. Eksp Klin Farmakol. 2014;77(8):34-8. Russian. PubMed PMID: 25335389.

11: Vyshtakalyuk AB, Nazarov NG, Zueva IV, Lantsova AV, Minnekhanova OA, Busygin DV, Porfiryev AG, Evtyugin VG, Reznik VS, Zobov VV. Study of hepatoprotective effects of xymedon. Bull Exp Biol Med. 2013 Sep;155(5):643-6. PubMed PMID: 24288729.

12: Svatko LG, Krasnozhen VN, Pokrovskaia EM. [A method for the combined treatment of chronic cystic sinusitis]. Vestn Otorinolaringol. 2008;(6):7-9. Russian. PubMed PMID: 19156109.

13: Revin VV, Yudanov MA, Maksimov GV. Lipid composition of rat somatic nerves under the effect of damaging factors. Bull Exp Biol Med. 2006 Aug;142(2):191-3. English, Russian. PubMed PMID: 17369937.

14: Masgutov R, Raginov I, Fomina G, Kozlova M, Chelyshev Y. Stimulation of the rat's sciatic nerve regeneration by local treatment with Xymedon. Cell Mol Neurobiol. 2006 Oct-Nov;26(7-8):1413-21. Epub 2006 May 26. PubMed PMID: 16729249.

15: Raginov IS, Cherepnev GV, Garaev RS. [Effect of xymedone on high-voltage-activated Ca2+ currents in pyramidal neurons of the entorhinal cortex]. Eksp Klin Farmakol. 2006 Jan-Feb;69(1):18-20. Russian. PubMed PMID: 16579053.

16: Pogorel'tsev VI, Garmonov SY, Polekhina OV, Reznik VS. Interspecies pharmacokinetics of xymedon. Bull Exp Biol Med. 2005 Jul;140(1):58-60. PubMed PMID: 16254621.

17: Ziyatdinova GK, Voloshin AV, Gilmutdinov AKh, Budnikov HC, Ganeev TS. Application of constant-current coulometry for estimation of plasma total antioxidant capacity and its relationship with transition metal contents. J Pharm Biomed Anal. 2006 Mar 3;40(4):958-63. Epub 2005 Oct 20. PubMed PMID: 16242890.

18: Skorokhodkina OV, Tsibul'kin AP, Tsibul'kina VN. [Immunopharmacological activity of xymedone in patients with atopic bronchial asthma]. Eksp Klin Farmakol. 2004 Sep-Oct;67(5):31-3. Russian. PubMed PMID: 15559633.

19: Raginov IS, Chelyshev YA, Shagidullin TF. Interaction of sensory neurons and satellite cells during stimulation of nerve regeneration. Neurosci Behav Physiol. 2004 Jan;34(1):79-81. PubMed PMID: 15109086.

20: Raginov IS, Chelyshev IuA. [Post-traumatic survival in different subpopulations of sensory neurons]. Morfologiia. 2003;124(4):47-50. Russian. PubMed PMID: 14628555.